Search

everythinglearnresearchcommunity

for

Search:↓

A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.

Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might reduce it. AST decreases recurrence-free survival but doesn't affect overall survival or progression-free survival. More research is needed to understand AST's benefits.

Valproic acid helps delay hair loss and increases survival time for high-grade glioma patients undergoing radiation therapy.

Adding hormone therapy to radiation improves survival for high-risk prostate cancer recurrence but has side effects.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

Removing lymph nodes does not improve survival for advanced ovarian cancer and may cause more complications.

The combination treatment showed a higher response rate but no significant survival benefits.

Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might decrease the risk. AST also lessens the chance of cancer coming back but doesn't really affect survival rates. More research is needed to understand AST's benefits for different bladder cancers.

Sorafenib helps some advanced cancers alone or with other treatments, but not all, and research continues to improve its use.

Bendamustine, often combined with other drugs, is effective and less toxic for certain blood cancers, but less effective for young, fit patients with CLL.

Pegylated liposomal doxorubicin is as effective as conventional doxorubicin but causes fewer heart problems and side effects.

Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.

Ripretinib is effective and safe for treating advanced GIST in Chinese patients, particularly for non-gastric GISTs.

The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.

Certain HSD3B1 gene types are linked to worse prostate cancer outcomes and affect treatment response and other health conditions.

Docetaxel and oxaliplatin are effective and have manageable side effects for recurrent platinum-sensitive ovarian cancer.

Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.

Targeted therapies for advanced skin cancer often cause hair and nail problems, which need managing to avoid changing the treatment dose.

VDC-1101 shows potential as a treatment for canine cutaneous T-cell lymphoma.

The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.

Combining gemcitabine with paclitaxel is more effective than with pemetrexed for advanced lung cancer.

2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

Older ovarian cancer patients live longer and tolerate weekly chemotherapy better than three-weekly treatments.

The Li-Pa/Ca and Do/Ca chemotherapy regimens for serous ovarian cancer showed better short-term and long-term results than the Pa/Ca regimen.

Blood tests for tumor cells could improve prostate cancer diagnosis and treatment; hair loss severity linked to a gene affecting prostate conditions.

Two cycles of ABVD chemotherapy followed by 20 Gy radiotherapy is the new standard for early-stage Hodgkin lymphoma due to lower toxicity and similar effectiveness.

PEGylated liposomal doxorubicin improves cancer treatment effectiveness and reduces side effects like heart damage and hair loss.

Adding celecoxib to chemotherapy improves survival and quality of life for gastric cancer patients with positive COX-2.

Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.